⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038898 | 1.00 | — | — | |
| SCHEMBL3387043 | 0.91 | CES2 (0.41) | — | |
| SCHEMBL3387041 | 0.91 | CES2 (0.41) | — | |
| SCHEMBL1221414 | 0.84 | — | — | |
| SCHEMBL14451085 | 0.84 | — | — | |
| SCHEMBL22181075 | 0.80 | CES1 (0.36) | — | |
| SCHEMBL24829478 | 0.78 | FAAH (0.40) | — | |
| SCHEMBL14137675 | 0.73 | CES2 (0.39) | — | |
| SCHEMBL8316292 | 0.73 | SPHK2 (0.31) | — | |
| SCHEMBL23398198 | 0.73 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220001022-A1 | Immunoconjugates Targeting HER2 | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2021-09-09 | — | — | US | disclosed |
| WO-2020190731-A1 | IMMUNOCONJUGATES TARGETING HER2 | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190762-A1 | MACROMOLECULE-SUPPORTED TLR AGONISTS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190734-A1 | IMMUNOCONJUGATES TARGETING PD-L1 | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190760-A1 | IMMUNOCONJUGATES TARGETING CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-7301037-B2 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |